Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monensin is a polyether antibiotic and ionophore produced by the bacterium Streptomyces cinnamonensis. It is primarily used as a veterinary drug in ruminant animal feeds to prevent coccidiosis in poultry and as a growth promoter in cattle. Monensin acts by forming complexes with monovalent cations (such as Na+, K+, Li+), facilitating their transport across lipid membranes. This disrupts normal ion gradients, particularly functioning as an Na+/H+ antiporter, which alters microbial activity in the rumen and inhibits protozoal growth. Its use increases feed efficiency and milk production efficiency in dairy cows[1][2][3][4][5]. Monensin also blocks intracellular protein transport and has been used experimentally to block Golgi transport[4]. It was the first polyether antibiotic whose structure was elucidated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monensin.